BeOne Medicines (ADR)
Develops and commercializes oncology medicines through an in-house global model.
Something off on this page? Send us feedback.
Profile
Discovers, develops, manufactures, and commercializes oncology medicines, led by BRUKINSA and TEVIMBRA. A global in-house model connects blood-cancer and solid-tumor research with commercialization, while the business depends on country-specific approvals, reimbursement, intellectual property, manufacturing execution, and a small number of products.
Develops and commercializes oncology medicines through an in-house model spanning research, clinical development, manufacturing, and commercialization. BRUKINSA, a BTK inhibitor, is the commercial anchor; TEVIMBRA, an anti-PD-1 antibody, adds a second major proprietary franchise, alongside PARTRUVIX and in-licensed products such as XGEVA, BLINCYTO, and KYPROLIS.
Operates through major hubs in Basel, Beijing, Cambridge, San Carlos, and Hopewell, with products approved across many markets and research programs covering blood cancers and solid tumors. Founder-led continuity and control from discovery through commercialization define the operating model.
Depends on country-specific approvals, reimbursement, intellectual-property protection, manufacturing execution, and a small number of commercial products. Patent disputes involving BRUKINSA and shifting partnership rights around TEVIMBRA also shape the commercial perimeter.
Company facts
Key statistics
Year to date +17.9% · Average volume (30d) 373.7K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | Wolfe Research | Reiterate | Outperform | $340 | $370 | |
| Aug 6, 2026 | Barclays | Reiterate | Overweight | $403 | $407 | |
| Jul 14, 2026 | Barclays | Reiterate | Overweight | $409 | $403 | |
| Jul 13, 2026 | Jefferies | Upgrade | Buy | Positive | ||
| Jul 12, 2026 | Jefferies | Reiterate | Buy | $420 | $380 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | $1.63 | $2.05 | +25.8% | $1.62B | $1.71B | +4.9% | +1.40% |
| May 6, 2026Q1 FY26 | $0.73 | $1.96 | +168.5% | $1.48B | $1.51B | +2.5% | +1.17% |
| Feb 26, 2026Q4 FY25 | $1.60 | $0.58 | −63.7% | $1.47B | $1.50B | +2.2% | −1.67% |
| Nov 6, 2025Q3 FY25 | $0.72 | $1.09 | +51.4% | $1.45B | $1.41B | −2.7% | −3.73% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.12B | $1.32B | $1.41B | $1.50B | $1.51B | $1.71B | |
| Gross profit | $952.3M | $1.15B | $1.22B | $1.36B | $1.35B | $1.53B | |
| Operating income | $11.1M | $87.9M | $163.1M | $185.0M | $249.9M | $325.0M | |
| Net income | $1.3M | $94.3M | $124.8M | $66.5M | $227.4M | $237.0M | |
| Diluted EPS | $0.01 | $0.84 | $13.52 | $6.76 | $25.35 | $26.65 | |
| Gross margin | 85.2% | 87.5% | 86.1% | 90.5% | 89.0% | 89.8% | |
| Operating margin | 1.0% | 6.7% | 11.5% | 12.4% | 16.5% | 19.1% |
Fiscal years (4-quarter sums)FY21 $1.18B · FY22 $1.42B · FY23 $2.46B · FY24 $3.81B · FY25 $5.34B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $5.10B · Total debt $1.14B · Total assets $9.18B · Shareholders' equity $5.17B
Dividends
No dividends on record.
Ownership
Shares outstanding 106.86M · Float 67.18M · 62.9% free float
Insiders — filings are in the shares behind the receipt.
This listing is a depositary receipt and the Form 4 positions here are filed in the shares behind it, a different unit from the share count and in a ratio the filings never state, so no insider percentage is shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 8.80M | 8.24% | 13F | Aug 14, 2026 |
| Primecap Management Co/CA/ | 5.01M | 4.69% | 13F | Aug 14, 2026 |
| Capital International Investors | 4.21M | 3.94% | 13F | Aug 12, 2026 |
| FMR LLC | 2.48M | 2.32% | 13F | Aug 13, 2026 |
| Capital World Investors | 2.25M | 2.11% | 13F | Aug 12, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 25, 2026 | Xiaobin Wu | officer: President and COO | −280 | $380.00 |
| Aug 11, 2026 | Chan Henry Lee | officer: SVP, General Counsel | −2,666 | $360.00 |
| Aug 12, 2026 | John Oyler | director, officer: Chief Executive Officer | −54,892 | $358.15 |
| Aug 11, 2026 | John Oyler | director, officer: Chief Executive Officer | −70,907 | $361.90 |
| Aug 10, 2026 | John Oyler | director, officer: Chief Executive Officer | −115,011 | $357.87 |
Peers
- AstraZeneca (ADR)
Closest global BTK-class rival across major B-cell malignancies
- AbbVie
Direct BTK rivalry through jointly marketed IMBRUVICA
- Merck
Global PD-1 benchmark across overlapping solid tumors
- Eli Lilly
Non-covalent BTK challenger in relapsed blood cancers
- Bristol-Myers Squibb
PD-1 rival in upper gastrointestinal cancers
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BeOne Medicines (ADR) | $366.73 | −0.01% | $39.19B | 5.1 | 46.7 | 6.9 | +29.6% |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Merck | $148.19 | −0.08% | $366.18B | 118.7 | 17.2 | 5.5 | +5.1% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Median | 39.4 | 16.8 | 5.5 | +6.4% |